Advertisement
There is variation in the net clinical benefit of anticoagulants based on variation in published atrial fibrillation stroke rates

Net Benefit of Anticoagulants for A-Fib Varies With Stroke Rate

0
Benefit of warfarin anticoagulation varies with varying published stroke rates
Every nine minutes

Dozens of Medical Groups Join Forces to Improve Diagnoses

0
Diagnostic error is the most common cause of medical errors that patients report
Preoperative statin therapy is associated with higher long-term survival following abdominal aortic aneurysm repair

Statins Improve Long-Term Survival After AAA Repair

0
Findings in those taking statins before abdominal aortic aneurysm repair or initiating before discharge
Risk of cardiotoxicity is higher for patients receiving trastuzumab and/or anthracyclines for the treatment of breast cancer

Cardiac Monitoring Needed for High-Risk Breast Cancer Patients

0
Trastuzumab, certain chemo treatments increase patient risk of heart failure
On average

Hospitals Charge 479 Percent of Cost of Drugs on Average

0
Seventeen percent of hospitals charge 700 percent of cost; 8 percent have markup over 1,000 percent
Allopurinol dose escalation is not associated with reductions in mortality risk among patients with gout

Allopurinol Dose Escalation for Gout Doesn’t Improve Mortality

0
Linked to small increase in mortality; at 2 years, 31 percent of dose escalators achieved serum urate goal
Children with a history of neonatal abstinence syndrome are more likely to be referred for a disability evaluation and meet criteria for a disability

Educational Disabilities More Likely With Neonatal Abstinence

0
Children with neonatal abstinence syndrome more likely to be evaluated, meet criteria for disability
There is an urgent need for clinical trials to investigate the use of cannabinoids in pediatric patients with neurological disorders

Cannabinoid Trials Needed for Peds Neurologic Disorders

0
Canadian researchers urge rigorous clinical trials in pediatric patients
The prevalence of type 1 and type 2 diabetes is 0.5 and 8.5 percent

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

0
Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults
Rivaroxaban does not lower risk of symptomatic venous thromboembolism and related death in medical patients after hospital discharge

No Clear Benefit for Rivaroxaban After Hospital Discharge

0
Incidence of major bleeding low with rivaroxaban, but clot risk not lower